バイオ統計学･臨床疫学
Biostatistics and Clinical Epidemiology
教 授 折笠 秀樹 Hideki Origasa
◆ 原原原原 著著著著
1) Atarashi H., Inoue H., Okumura K., Yamashita T., Origasa H., for the J-RHYTHM Registry Investigators. : Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation – The J-RHYTHM Registry study design. J. Cardiol., 57: 95-99, 2011.
2) Takahashi C., Okudera H., Origasa H., Takeuchi E., Nakamura K., Fukuda O., Date I., Tokumori T., Aruga T., Sakamoto T., Kobata H., and Ohta T. : A simple and useful coma scale for patients with neurologic emergencies: the Emergency Coma Scale.
Am. J. Emerg. Med., 29(2): 196-202, 2011.
3) Itakura H., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., Shirato K., Matsuzawa Y., for the JELIS Investigators. : Relationships between plasma fatty acid composition and coronary artery disease. J. Atheroscler. Thromb., 18(2): 99-107, 2011.
4) Shigehara K., Sugimoto K., Konaka H., Iijima M., Fukushima M., Maeda Y., Mizokami A., Koh E., Origasa H., Iwammoto T., and Namiki M. : Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male, 14(1): 53-58, 2011.
5) Atarashi H., Inoue H., Okumura K., Yamashita T., Kumagai N., Origasa H., for the J-RHYTHM Registry Investigators. : Present status of anticoagulant treatment in Japanese patients with atrial fibrillation – A report from the J-RHYTHM Registry.
Circ. J., 75: 1328-1333, 2011.
6) Uchiyama S., Ikeda Y., Urano Y., Horie Y., and Yamaguchi T. (Origasa H. listed in the appendix as a statistical adviser) : The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. Cerebrovasc. Dis., 31: 601-613, 2011.
7) Ogawa S., Shinohara Y., and Kanmuri K. (Origasa H. listed in the appendix as a chair of data and safety monitoring committee) : Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation – The ARISTORLE-J Study-. Circ. J., 75: 1852-1859, 2011.
8) Origasa H., Goto S., Shimada K., Uchiyama S., Okada Y., Sugano K., Hiraishi H., Uemura N., Ikeda Y., on behalf of the MAGIC Investigators. : A prospective cohort study of gastrointestinal complications and vascular disease in patients taking aspirin: rationale and design of the MAGIC study. Cardiovasc Drugs Ther., 25(6): 551-560, 2011.
9) Kawahara M., Tada H., Tokoro A., Teramukai S., Origasa H., Kubota K., Shinkai T., Fukushima M., and Furuse K. : Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01). BMC Cancer, 11: 256, 2011.
10) J-RHYTHM Registry Investigators (Origasa H. to be appeared in Appendix as a statistician). : Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan: subanalysis of the J-RHYTHM Registry. Circ. J., 75: 2357-2362, 2011.
11) Goto S., Ikeda Y., Shimada K., Uchiyama S., Origasa H., Kobayashi H., on behalf of the J-TRACE Investigators. : One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation: results from the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ. J., 75: 2598-2604, 2011.
12) 小谷英太郎，奥村 謙，井上 博，山下武志，新 博次，折笠秀樹：我が国で用いられているプロトロンビン時間 国際標準比（INR）測定用試薬の国際感度指数（ISI）値とその問題点：J-RHYTHM Registryからの検討．心電図，
31（3）：225-233，2011．
◆ 総総総総 説説説説
1) 折笠秀樹：臨床研究の計画・実施・報告・評価に関する現状および論点．薬理と治療，39（1）：51-65，2011．
2) 内山真一郎，後藤信哉，折笠秀樹，島田和幸，池田康夫，J-TRACE研究実施委員会：脳卒中の登録・観察研究：J-TRACE． 分子脳血管病，10（2）：158-162，2011．
3) 鈴木則宏，佐藤志樹，EVEREST学術委員会（内山真一郎，岡田 靖，折笠秀樹，後藤信哉，重松 宏，代田浩之，
田中耕太郎，寺山靖夫，宝金清博，松本昌泰，峰松一夫，宮本 亨）：脳卒中の登録・観察研究：EVEREST．分子 脳血管病，10（2）：163-167，2011．
4) 折笠秀樹：臨床試験における統計解析．Congnition and Dementia，10（3）：280-283，2011．
5) 折笠秀樹：臨床研究の企画～質の高い臨床研究を目指す～．Medicament News，No.2063：4-5，2011．
◆ 学会報告学会報告学会報告学会報告
1) Okada Y. and EVEREST Steering Committee (Suzuki N., Houkin K., Terayama Y., Daida H., Uchiyama S., Goto S., Shigematsu H., Origasa H., Tanaka K., Minematsu K., Miyamoto S., Matsumoto M.) : Predictive value of the Essen stroke risk score for the recurrence of non-cardioembolic stroke in Japanese patients: The results from the EVEREST registry.
International Stroke Conference (poster), 2011, 2, 9-11, Los Angeles.
2) Matsumoto M., Kohriyama T., Yamawaki T., Ohtsuki T., hosomi N., Fukushima M., Nagai Y., Minematsu K., Yokota C., Origasa H., Uchiyama S., and Ibayashi S. : Japan Statin Treatment Against Recurrent Stroke (J-STARS). 20th European Stroke Conference, 2011, 5, 24-27, Hamburg.
3) Origasa H., Sumi S., Suzuki N., and the EVEREST Steering Committee. : A new score to predict recurrent cardiovascular events within a year after non-cardioembolic ischemic stroke. ESC (European Society of Cardiology) Congress, 2011, 8, 27-31, Paris.
4) Miyauchi K., Daida H., and the PACIFIC Registry Steering Committee (Origasa H was a member of the steering committee) : The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischaemic Coronary attack) Registry: one-year follow-up data of a 2-year study in patients initially hospitalized with acute coronary syndrome in Japan. ESC (European Society of Cardiology) Congress, 2011, 8, 27-31, Paris.
5) Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Shoji T., Sakamaki Y., Miyasaka N., and Koike T. : Efficacy of certolizumab pegol without methotrexate co-administration in patients with active rheumatoid arthritis: results from the Japanese HIKARI study. 2011 Annual Scientific Meeting of the American College of Rheumatology (ACR 2011), 2011, 11, 5-9, Chicago.
6) Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Iwai K., Sakamaki Y., Miyasaka N., and Koike T. : Efficacy and safety of certolizumab pegol plus methotrexate in rheumatoid arthritis patients with inadequate response to methotrexate: results from the Japanese J-RAPID study. 2011 Annual Scientific Meeting of the American College of Rheumatology (ACR 2011), 2011, 11, 5-9, Chicago.
7) Akizawa T., Origasa H., Kameoka C., on behalf of the Bixalomer Study Group. : A phase III, sevelamer HCI-controlled study of bixalomer in chronic kidney disease (CKD) patients on hemodialysis with hyperphosphatemia. American Society of Nephrology Kidney Week 2011, 2011, 11, 8-13, Philadelphia.
8) Fujita T., Koyama A., Gejyo F., Origasa H., Isono M., and Kiriyama T. : Sustained-release tablets of orally-active prostacyclin analogue, beraprost sodium, for patients with non-diabetic chronic renal failure. American Society of Nephrology Kidney Week 2011, 2011, 11, 8-13, Philadelphia. [J. Am. Soc. Nephrol., 22: 429A, 2011.]
9) Goto S., Shimada K., Uchiyama S., Origasa H., Kobayashi H., Nagao T., Kawamura A., Kitagawa K., Ikeda Y., for the J-TRACE Investigators. : Risk prediction models for cardiovascular events in patients with stroke, myocardial infarction and atrial fibrillation in Japan. American Heart Association 2011, 2011, 11, 12-16, Orlando.
10) 林 克洋，土屋弘行，竹内章彦，星 学，家口 尚，青野勝成，田地野崇宏，山田 仁，帖佐悦男，坂本武郎，坂 山憲史，木谷彰岐，横内雅博，永野 聡，礒部研一，前原博樹，當銘保則，折笠秀樹，赤澤宏平：高悪性度骨・軟 部腫瘍に対するカフェイン併用化学療法の多施設共同研究．第 84回日本整形外科学会学術総会，2011，5，12-15，
東京．[日本整形外科学会雑誌，85（6）：S840，2011．]
11) 鴨内正浩，熊谷直子，岡田 靖，折笠秀樹，北園孝成，山口武典：日本脳梗塞患者の再発リスクスコア．第20回日 本脳ドック学会総会，2011，7，8-9，東京．
12) 熊谷直子，折笠秀樹，長尾毅彦，竹川英宏，奥原義保，山口武典：アテローム血栓性脳梗塞発症後の症候変化のパ ターンとその関連因子．第20回日本脳ドック学会総会，2011，7，8-9，東京．
13) 板倉弘重，横山光宏，松﨑益徳，斎藤 康，折笠秀樹，松澤祐次，JELIS 研究会：Relationship between plasma
eicosapentaenoic acid/ arachidonic acid (EPA/AA) ratio and coronary artery disease. 第43回日本動脈硬化学会，2011，7，
15-16，札幌．
14) Sasaki J., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Matsuzawa Y. : Relationship between coronary artery disease and LDL-C and/or non HDL-C, and effect of EPA on the risk of coronary artery disease in hypercholesterolemic patients under treatment with statins: sub-analysis of the JELIS trial. 第43回日本動脈硬化学会，2011，7，15-16，札幌．
15) Isshiki T., Igarashi K., Nakamura M., Ikari Y., Kimura T., Yokoi H., Ueno T., on behalf of CLEAN Investigators (Origasa H to be a member of independent data monitoring committee). : Clopidogrel trial in patients with elective percutaneous coronary intervention or stable anginaand old myocardial infarction; safety and efficacy of clopidogrel compare to those of ticlopideine
in Japanese. 第20回日本心血管インターベンション治療学会，2011，7，21-24，Osaka．
16) Uchiyama S., Goto S., Origasa H., Shimada K., Kobayashi H., Isozaki M., Ikeda Y., on behalf of the J-TRACE Investigators. : The Japan registry for atrial fibrillation, coronary or cerebrovascular events (J-TRACE). Symposium 3 (SS-S3), 第36回日本 脳卒中学会，2011，7，30 - 8，1，京都．
17) Inoue H., Atarashi H., Okumura K., Yamashita K., Origasa H., for the J-Rhythm Registry Investigators. : Deviation of anticoagulation levels from the guidelines of JCS for patients with atrial fibrillation: a sub-analysis of J-Rhythm registry. 第75 回日本循環器学会総会，2011，8，3-4，横浜．
18) Goto S and the EVEREST Steering Committee (Suzuki N., Houkin K., Terayama Y., Diada H., Uchiyama S., Shigematsu H., Origasa H., Tanaka K., Minematsu K., Miyamoto S., Matsumoto M., Okada Y., Sato M) : OE-013: Lower Risk of ischemic coronary events than cerebrovascular events in Japanese outpatients registered within 6 month after onset of the latest ischemic stroke: sub-analysis of the EVEREST Registry. 第75回日本循環器学会総会，2011，8，3-4，横浜．
19) 細川 歩，小川浩平，板谷優子，安藤孝将，梶浦新也，月岡雄治，小林隆司，堀川直樹，小林由夏，吉岡 亮，折 笠秀樹，杉山敏郎：進行胃癌に対するS-1/cisplatinとS-1/docetaxelの交替療法の第I/II相臨床試験成績．第49回日 本癌治療学会，2011，10，27-29，名古屋．
20) 折笠秀樹：臨床研究デザイン入門．第48回日本リハビリテーション医学会（教育講演），2011，11，3，幕張．
◆ そのそのそのその他他他他
1) 折笠秀樹：正常圧水頭症シャント術レジストリーの中間報告．厚生労働省科学研究費補助金・難治性疾患克服総合 研究事業：「正常圧水頭症の疫学・病態と治療に関する研究（H20-難治-一般-017）」平成 22 年度総括・分担研究報 告書，62-63，2011.
2) 折笠秀樹：臨床試験と患者登録研究．医報とやま，No.1525(H23.4.15)：11-12，2011．
3) 折笠秀樹，熊谷直子：漢方薬のインフルエンザワクチンアジュバント療法に関する臨床試験の計画及び統計解析に 関する研究．厚生労働省科学研究費補助金・医療技術実用化総合研究事業（臨床研究推進研究事業）：「漢方薬によ るワクチンアジュバント効果の検討と臨床応用」平成22年度総括・分担研究報告書，52-56，2011．
4) 折笠秀樹：最近の糖尿病に関する研究論文：医学統計の視点から．リリーブラッシュアップセミナー2011-春（招聘 講演），2011，7，31，東京．
5) 折笠秀樹：臨床論文を読むときに知っておくべき統計手法．北野病院コアレクチュア（招聘講演），2011，8，26， 大阪．
6) 折笠秀樹：最近の糖尿病に関する研究論文：医学統計の視点から．リリーブラッシュアップセミナー2011-秋（招聘 講演），2011，11，27，東京．
